

# Curriculum Vitae

## Kelly Knight, CCRP

### Research Affiliation

Elligo Health Research, Inc., 2022- Present  
11612 Bee Cave Road, Bldg. 1, Suites 100 & 150, Austin, TX 78738

### Research Affiliation

Arkansas Center for Sleep Medicine, PLLC  
11219 Financial Centre Parkway, Suite 101  
Little Rock, AR 72211  
(501) 553-9987 x108  
(501) 553-9986 FAX

### Research Affiliation

Preferred Research Partners, Inc.  
11219 Financial Centre Parkway, Suite 320  
Little Rock, AR 72211  
(501) 553-9987 x108  
(501) 553-9986 FAX

Signature: \_\_\_\_\_

*K Knight*

Date: \_\_\_\_\_

*22 Aug 2022*

## **Kelly Diane Knight, CCRP**

**[kknight@preferredresearchpartners.com](mailto:kknight@preferredresearchpartners.com)**

**501-553-9987 x.108**

### **Office**

**Paul E. Wylie, M.D., P.A. (Clinic Office)**

**11219 Financial Center Parkway, Suite 315**

**Little Rock, AR 72211**

**Phone: 501-661-9191 x.108 Fax: 501-661-1991**

**Arkansas Center for Sleep Medicine, PLLC (Polysomnography Lab)**

**11219 Financial Center Parkway, Suite 101**

**Little Rock, AR 72211**

**Phone: 501-553-9987 Fax: 501-661-1991**

**Preferred Research Partners, Inc.**

**11219 Financial Centre Parkway, Suite 320**

**Little Rock, AR 72211**

**Phone: 501-553-9987 x.108 fax: 501-553-9986**

### **Education**

**2001-2003: Pulaski Technical College**

**Core Education Courses**

**January 2000 — May 2000 Louisiana Technical College Certificate for  
Nursing Assistant**

### **Certifications/Licensures**

**SOCRA CCRP certification number: 36869**

### **Work Experience**

**January 2009-present:**

**Study Coordinator, Preferred Research Partners, Inc.- Little Rock, AR**

**IRB submissions, marketing, recruiting patients, ensuring all equipment functional & calibrated, patient safety monitoring, informed consent process, patient care, CRF and source documentation completion, creation of source documents, regulatory, filing, scheduling, AE/SAE reporting, laboratory collection and processing.**

**July 2007-present:**

**Study Coordinator, Arkansas Center for Sleep Medicine- Little Rock, AR**

**Duties include IRB submissions, marketing, recruiting patients, ensuring all equipment functional & calibrated, patient safety monitoring, informed consent process, patient care, CRF and source documentation completion, creation of source documents, regulatory, filing, scheduling, AE/SAE reporting, laboratory collection and processing.**

July 2005-July 2006:

Study Coordinator, Gulf Coast Research Associates, LLC-Baton Rouge, La.

Recruiting patients, patient safety monitoring, informed consent process, patient care, CRF and source documentation completion, filing, scheduling, AE/SAE reporting, laboratory processing.

2003-2006: Caring Hands Home Health Services Baton Rouge, LA

Patient Care Attendant/Caregiver

Responsible for assisting an autistic child with activities of daily living, completing daily progress notes, following specific curriculums and behavior protocols, creation of compliance gaining and maintaining techniques and following through with them and keeping up with detailed daily records of progression/digression.

2000-2002: Life Skills Technician, Arkansas Pediatric Facility North Little Rock, AR Duties providing complete care for physically and /or mentally disabled pediatrics in a long-term care facility. Completing detailed charting and record keeping of food/liquid intake, voids/bms, positioning, behavior, and overall well-being.

### Presentations & Academic Research

2/2010: "Effective Subject Recruitment & Retention Strategies" presentation to all RLS sites on A0081185 for United Biosource Corporation

### Research Experience

#### Pharmaceutical:

- 2005: Boehringer Ingelheim ProFess — Second Stroke Prevention Study
- 2005: GSK, Restless Legs Syndrome
- 2006: Xenoport, Restless Legs Syndrome
- 2007: Xenoport, Restless Legs Syndrome (PK)— XP08
- 2007: Takeda, Chronic Insomnia – 01-05-TL-375-069
- 2007: Xenoport, Restless Legs Syndrome – XP053
- 2007: Takeda, Delayed Sleep Phase Syndrome (polysomnography)— 01-04-TL-375-044
- 2007: Sanofi-Aventis, Sleep Maintenance— LTE6673 (SAMS)
- 2007: Xenoport, Restless Legs Syndrome – XP055
- 2007: Organon, Chronic Primary Insomnia (polysomnography) – 176002
- 2007: Organon, Chronic Primary Insomnia – 176004
- 2007: Pfizer, Primary Insomnia – A4251037
- 2008: Pfizer, Non-Restorative Sleep (polysomnography) – A4251033
- 2008: Lilly, Primary & Secondary Insomnia – 12K-MC-ZZAD
- 2009: Pfizer, Restless Legs Syndrome – A0081186
- 2009: Pfizer, RLS Patient Reported Outcomes – PI6034A
- 2009: Pfizer, Fibromyalgia & Sleep Maintenance Insomnia – A0081165
- 2009: Pfizer, Restless Legs Syndrome (polysomnography) – A0081185
- 2009: Romark Laboratories/SGS, Acute Uncomplicated Influenza – RM01-2027
- 2010: Pfizer, Restless Legs Syndrome – A0081184

- 2010: Sepracor, Attention Deficit Disorder & Insomnia in Children (polysomnography) – 190-246
- 2010: Sepracor, Attention Deficit Disorder & Insomnia in Children (rollover & treatment naïve) – 190-247
- 2010: Romark Laboratories/SGS, Acute Uncomplicated Influenza – RM08-3001
- 2010: Eli Lilly & Company, Sickle Cell Anemia – H7T-MC-TAEK(a)
- 2010: AstraZeneca, Major Depressive Disorder – D413C00004
- 2010: Furiex Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – 27018966IBS2001
- 2011: AstraZeneca, Opioid Induced Constipation – D3820C00005 (KODIAC 5)
- 2011: AstraZeneca, Opioid Induced Constipation – D3820C00008 (KODIAC 8)
- 2011: Anchen Pharmaceuticals, Chronic Idiopathic Constipation – 71060001
- 2011: Impax Pharmaceuticals, Restless Legs Syndrome – IPX159-B11-02
- 2011: UCB, Restless Legs Syndrome in Adolescents – SP1004
- 2011: Bristol Myers Squibb, Type II Diabetes & Hypertension – MB102073
- 2011: Apotex Inc. – Chronic Idiopathic Constipation – LUBI-SGCP-05SB07-CE
- 2012: Synergy Pharmaceuticals, Chronic Idiopathic Constipation – SP304-20210
- 2012: UCB, Restless Legs Syndrome in Adolescents – SP1005
- 2012: Bristol Myers Squibb, Type II Diabetes & Hypertension – MB102077
- 2012: Forest Research Institute, Hypertension – NAC-MD-01
- 2012: Ardea BioSciences, Gout – RDEA594-301
- 2012: Orexigen, Obesity & Cardiovascular Outcomes – NB-CVOT
- 2012: Novartis, High Triglycerides – CLCQ908C2201
- 2012: Furiex Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – 27018966IBS3001
- 2012: Lexicon Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – LX1033-1.201
- 2012: Tioga Pharmaceuticals, Diarrhea Predominant Irritable Bowel Syndrome – ASMP3001
- 2012: Shionogi, Inc., Opioid Induced Constipation – 1107V9221
- 2012: Tsumura Pharmaceuticals, Crohn's Disease – TU100P2T2
- 2012: Coronado Biosciences, Crohn's Disease – CNDO-201-003
- 2012: Shire, GERD – SPD557-206
- 2012: UCB, Healthy Adult, Phase I – SP1031
- 2012: UCB, Restless Legs Syndrome – RL0003
- 2012: GSK, Restless Legs Syndrome – RXP114025
- 2013: Ardea BioSciences, Gout – RDEA594-306
- 2013: Dr. Reddy's Laboratories, Chronic Idiopathic Constipation – DRL-USG01-L/2012
- 2013: Purdue Pharma L.P., Chronic Low Back Pain & Opioid-Induced Constipation – ONU3705
- 2013: Cubist Pharmaceuticals, Inc., Opioid-induced Constipation – 5945-SOIC-12-05
- 2013: Cubist Pharmaceuticals, Inc., Opioid-induced Constipation – 5945-OIC-12-04
- 2013: Ferring International Pharmascience Center US, Inc., Chronic Idiopathic Constipation – 000080
- 2013: Ferring International Pharmascience Center US, Inc., Chronic Idiopathic Constipation – 000081

- 2013: Synergy Pharmaceuticals, Inc., Chronic Idiopathic Constipation (OLE CIC) – SP304203-01
- 2013: Shionogi, Inc., Opioid Induced Constipation – 1315V9232
- 2013: Menarini, Diarrhea-Predominant Irritable Bowel Syndrome – NAK-07 (IRIS-4)
- 2013: Synergy Pharmaceuticals, Inc., Chronic Idiopathic Constipation (CIC3) – SP304203-00
- 2014: Evoke, Diabetic Gastroparesis – METO-IN-003
- 2014: Evoke, Diabetic Gastroparesis – METO-IN-004
- 2014: Eisai, Long-Term incidence of MACE events & conversion to Type II Diabetes Mellitus in Obese & Overweight Subjects with Cardiovascular Disease or Multiple CV Risk Factors – APD356-G000-401
- 2014: Takeda Development Center Americas, Inc., Gout – FEB-XR\_301
- 2014: Salix, Crohn's Disease – RECD3125
- 2014: Xenon, RLS Genetic Biomarker – XEN-RLS
- 2014: Targacept, Diabetic Gastroparesis – TC6499-12-CLP-005
- 2015: Rhythm Pharmaceuticals, Diabetic Gastroparesis – RM-131-009
- 2015: Jazz Pharmaceuticals, Narcolepsy & Excessive Daytime Sleepiness – 14-002
- 2015: Jazz Pharmaceuticals, Obstructive Sleep Apnea & Excessive Daytime Sleepiness – 14-003
- 2015: Jazz Pharmaceuticals, Long-term extension study for Obstructive Sleep Apnea or Narcolepsy with Excessive Daytime Sleepiness – 14-005
- 2015: Neurocrine Biosciences, Inc., Tardive Dyskinesia – NBI-98854-1304 (KINECT3)
- 2015: Theravance, Diabetic or Idiopathic Gastroparesis – 0099
- 2015: Synergy Pharmaceuticals, Inc., Irritable Bowel Syndrome-Constipation – SP304203-04
- 2015: Forest Research Institute, Inc., Irritable Bowel Syndrome-Constipation &/or Chronic Idiopathic Constipation – LIN-MD-10
- 2015: Edgemont Pharmaceuticals, Generalized Anxiety Disorder – EDG004-003
- 2015: Janssen Research & Development, Treatment-resistant Depression – ESKETINTRD3001 (TRANSFORM-1)
- 2015: Janssen Research & Development, Treatment-resistant Depression – ESKETINTRD3003 (SUSTAIN-1)
- 2015: Neurocrine Biosciences, Inc., Tardive Dyskinesia – NBI-98854-1402 (KINECT4)
- 2015: Naurex Inc., Major Depressive Disorder – NRX1074-C-202
- 2015: Gilead, Ulcerative Colitis – GS-US-326-1100
- 2015: Sunovion Pharmaceuticals, Adult Attention Deficit Hyperactivity Disorder (ADHD) – SEP360-301
- 2015: Ardelyx – IBS-C – TEN-01-301
- 2016: Ferring International Pharmascience Center US, Inc., Ulcerative Colitis – 000174
- 2016: Ferring International Pharmascience Center US, Inc., Ulcerative Colitis – 000175
- 2016: Conatus Pharmaceuticals, Non-alcoholic Steatohepatitis (NASH) – IDN-6556-12
- 2016: Synergy Pharmaceuticals, Irritable Bowel Syndrome with Constipation (IBS-C) – SP304203-06
- 2016: Janssen Research & Development, Treatment-resistant Depression – ESKETINTRD3008
- 2016: Eisai Pharmaceuticals, Elderly Insomnia – E2006-G000-304
- 2016: Luitpold Pharmaceuticals, Inc., Restless Legs Syndrome – 1VIT14037
- 2016: Braintree Laboratories, Chronic Constipation – BLI400-302

- 2016: Braintree Laboratories, Opioid Induced Constipation – BLI801-203
- 2016: Applied Proteomics – Colorectal Cancer Screening – API-CP001
- 2017: Takeda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – TAK906-1002
- 2017: Conatus Pharmaceuticals – Non-Alcoholic Cirrhosis – IDN-6556-17
- 2017: Shire Pharmaceuticals – Preschooler ADHD – SPD489-347
- 2017: Shire Pharmaceuticals – Preschooler ADHD – SPD489-348
- 2017: Allergan – Diabetic Gastroparesis – RLM-MD-01
- 2017: Braintree Laboratories, Bowel Prep for Colonoscopy – BLI4700-302
- 2017: Tonix Pharmaceuticals, Military-Related PTSD – TNX-CY-P301
- 2017: Vanda Pharmaceuticals, Inc. – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-2301
- 2017: Janssen – Major Depressive Disorder – CNT0136MDD2001
- 2017: Allergan – Pediatric Major Depressive Disorder – LVM-MD-11
- 2017: Allergan – Diabetic Gastroparesis – RLM-MD-04
- 2018: Allergan – Diabetic Gastroparesis – RLM-MD-03
- 2018: Tonix Pharmaceuticals, Military-Related PTSD – TNX-CY-P303
- 2018: Janssen Research & Development, Insomnia – 42847922ISM2005
- 2018: Shire Pharmaceuticals – Preschooler ADHD PK – SHP465-112
- 2018: Shire Pharmaceuticals – Adolescent ADHD – SHP465-308
- 2018: Shire Pharmaceuticals – Adolescent ADHD – SHP465-309
- 2018: AbbVie – Testosterone Replacement Therapy for Hypogonadism – M16-100
- 2018: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00061
- 2018: Idorsia Pharmaceuticals – Insomnia – ID-078A301
- 2018: Idorsia Pharmaceuticals – Insomnia – ID-078A303
- 2018: Janssen Research & Development – Major Depressive Disorder – 67953964MDD2001
- 2018: Neos Therapeutics – Attention Deficit Disorder in Children 4-6 y/o – NT0202.1009
- 2018: Neos Therapeutics – Attention Deficit Disorder in Children 4-6 y/o – NT0202.1010
- 2018: Tonix Pharmaceuticals - Military-Related PTSD – TNX-CY-P306
- 2018: Allergan – Diabetic Gastroparesis – 3071-305-020
- 2018: Ironwood Pharmaceuticals – GERD – C3718-302
- 2019: Tonix Pharmaceuticals - PTSD – TNX-CY-P302
- 2019: Apnimed – Obstructive Sleep Apnea – APN-002
- 2019: Aptinyx – Post-Traumatic Stress Disorder – NYX-783-2004
- 2019: Axsome Pharmaceuticals – Treatment-Resistant Depression – AXS05-301
- 2019: Biohaven Pharmaceuticals – Obsessive Compulsive Disorder – BHV4157-202
- 2019: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00071
- 2019: Takeda – Obstructive Sleep Apnea – Phase 1 – TAK-925-2001
- 2019: LG Chem – Gout with Hyperuricemia – LG-GDCL002
- 2019: Applied Therapeutics - Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure) – AT-001-2001
- 2019: Adare Pharmaceuticals – Eosinophilic Erosive Esophagitis – SP-1011-003
- 2019: Allergan - Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis – 3152-301-002
- 2019: Allergan – Constipation in Children 6-17 y/o – LIN-MD-64

- 2019: Allergan – Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C) – LIN-MD-66
- 2019: Allergan - Pediatric Participants (Age 2 to 5 Years) with Functional Constipation – LIN-MD-67
- 2019: Braintree Laboratories - Bowel Prep for Colonoscopy – BLI4900-302
- 2019: Phathom Pharmaceuticals – Erosive Esophagitis – EE-301
- 2019: Phathom Pharmaceuticals – H. Pylori – HP-301
- 2019: Vanda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-3301
- 2019: Vibrant Ltd – Chronic Idiopathic Constipation – V270
- 2020: Takeda – Idiopathic Hypersomnia – Phase 1 – TAK-925-2002
- 2020: Neurogastrx – Diabetic or Idiopathic Gastroparesis – NG101-201
- 2020: Allergan – Major Depressive Disorder – 2006-308-008
- 2020: Otsuka – Pediatric Attention Deficit Hyperactivity Disorder – 405-201-00010
- 2020: Apnimed – Obstructive Sleep Apnea – APN-006
- 2020: Janssen – Treatment-resistant Depression – 54135419TRD4005
- 2020: Janssen – Major Depression & Insomnia – 42847922MDD3002
- 2020: Novavax – COVID-19 Vaccine – 2019nCoV-301
- 2020: Supernus – ADHD in Preschoolers – 812P401
- 2021: Otsuka Pharmaceuticals – ADHD in Children – 405-201-00046

**Other:**

- 2009: Development of a Sleep Measure in Restless Legs Syndrome - Pfizer
- 2014: Colorectal Cancer Biomarker Specimen Collection Study – Applied Proteomics – API-CP001
- 2014: Sequencing Study to Investigate the Underlying Genetic Cause(s) in Subjects with Restless Leg Syndrome – Xenon Pharmaceuticals, Inc. –
- 2018: Freenome Holdings, Inc., Health Decisions – Colorectal Cancer Screening - FRE-001
- 2019: Guardant Health - Evaluation of ctDNA LUNAR-2 Assay in an Average Patient Screening Episode – 02-GI-002
- 2019: Apnimed – Obstructive Sleep Apnea – APN-002
- 2019: Aptinyx – Post Traumatic Stress Disorder – NYX-783-2004
- 2019: Axsome Pharmaceuticals – Treatment-Resistant Depression – AXS05-301
- 2019: Otsuka Pharmaceuticals – Post Traumatic Stress Disorder – 331-201-00071
- 2019: Takeda – Obstructive Sleep Apnea & Excessive Daytime Sleepiness – Phase 1- TAK-925-2001
- 2019: LG Chem – Gout with Hyperuricemia – LG-GDCL002
- 2019: Applied Therapeutics – Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to overt Heart Failure – AT – 001-2001
- 2019: Adare Pharmaceuticals – Eosinophilic Erosive Esophagitis – SP – 1011- 003
- 2019: Allergan- Liver Fibrosis in Adults with Nonalcoholic Steatohepatitis – 3152-301-002
- 2019: Allergan – Constipation in Children 6-17 y/0 – LIN – MD -64
- 2019: Allergan – Pediatric Participants with functional constipation or IBS-C – LIN-MD-66
- 2019: Allergan – Pediatric Participants with Functional Constipation – LIN-MD-67
- 2019: Braintree Laboratories – Bowel Prep for Colonoscopy – BLI4900-302
- 2019: Phathom Pharmaceuticals – H. Pylori – HP-301
- 2019: Vanda Pharmaceuticals – Diabetic or Idiopathic Gastroparesis – VP-VLY-686-3301
- 2019: Vibrant Ltd – Chronic Idiopathic Constipation – V270



2019: oprhoMed- IBS-D – OM-201

2020: Takeda – Idiopathic Hypersomnia – Phase 1 – TAK-925-2002

2020: Otsuka – ADHD in Children – Phase 1 – 405-201-00010

2020: Neurogastrix – Diabetic or Idiopathic Gastroparesis – NG101-201

2020: Guardant Health – Colorectal Cancer Screening – 02-GI-002 ECLISPE

2020: Janssen – Treatment Resistant Depression – 54135419TRD4005

2020: Allergan – major depressive Disorder – 2006-308-008

2020: Janssen – Major Depression and Insomnia – 42847922MDD3002

2020: Novavax – COVID-19 Vaccine – 2019nCoV-301

2021: Supernus- ADHD in preschoolers – 812P401

2021: Apnimed – Obstructive Sleep Apnea – APC-003

2021: Otsuka – Pediatric ADHD – Phase 1 – 405-201-00046

2021: Apnimed – APC-003-OLE

2021: Moderna – CMV Vaccine – mRNA-1647-P301

2021: Acerus Pharmaceuticals- Ambulatory BP Monitoring in Hypogonadism – NAT-2020-01

2021: Perdue Pharma LP – ADHD in Preschoolers & children – ADA4004

2021: Apnimed – Obstructive Sleep Apnea – APC-005

2021: Relmada – Major Depressive Disorder – REL-1017-302

2021: Relmada – Major Depressive Disorder – REL-1017-310

Device:

10/2007: Respiroics Inc. – The Impact of BIPAP AutoSVTM on Central Disregulated Breathing & Chronic Pain Patients (MR-0728-ASV3-MS)

10/2007: Restore Medical, Inc. – A Randomized, Placebo-Controlled Study of the Pillar Palatal Implant System with CPAP (protocol 845)

01/2008: Respiroics Inc. – Stardust Screening Study (MR-0735-SDSS-MS)

02/2008: Respiroics Inc. – Evaluation of a Positive Air Pressure Delivery Systems on Adherence & Outcomes (System One versus Better Together MR-0733-SYS1-SS)

08/2008: Respiroics Inc. – Evaluation of Software Enhancements to the Respiroics BiPAP AutoSV Device (MR-0731-ASV3-MS)

04/2009: Respiroics Inc. – User Preference & Validation Evaluation of the New BiPAP autoSV3 device (ST-0906-ASV3VAL-MS)

07/2009: Respiroics Inc. – Evaluation of the Q-Series Auto Device for the Treatment of OSA (ST-0925-AQVM-MS-G/W)

2/2010: Philips-Respiroics Inc. – Engineering Evaluation of the Next Generation of autoSV Devices (ST-0937-ASV4ENG-MS)

6/2010: Philips Respiroics – Evaluation of the Philips Respiroics BiPAP autoSV devices in subjects with Sleep Disorders (ST-1007-ASV4-MS)

12/2010: Philips Respiroics – Philips Respiroics BiPAP autoSV4 User Preference Trial (ST-1030-ASV4PREF-SS)

8/2011: Philips Respiroics – BiPAP autoSV System One Advanced in Patients with Chronic Pain and Sleep Disordered Breathing (SDBPM-2011-01)

9/2011: Philips Respiroics – Automated Graduated CPAP for Improved Adherence in Newly Diagnosed OSA Patients: Multicenter Trial (AR-1112-AGPAP-MS)

6/2012: Philips Respiroics – BiPAP autoSV Advanced in Central Apnea Patients (ST-1001-ASVWO-MS)

7/2012: Philips Respiroics – User Preference/Validation Evaluation of the New Phillips Respiroics PAP Application (ST1203-APP-MS)

12/2012: Cereve - A Multi-center Prospective, Blinded, Randomized Crossover Study to Compare the Cereve Sleep System at Two Different Temperatures in Primary Insomnia Patients (CIP-003)

6/2013: Philips Respiroics – Evaluation of the OmniLab 2.0 (ST-1311-OmniLab-MS)

6/2014: Philips Respiroics – BIG4 CPAP Study (PGI-BIG4-1331-MS)

7/2014: Philips Respiroics – Evaluation of Two Servo-Ventilation Devices (ST-1431-ASV Evaluation-ARK)

5/2015: Somnarus – Comparison of the Somnarus Sleep Apnea Diagnostic Technology SomnaPatch with Polysomnography (001)

7/2015: Philips Respiroics – Servo-Ventilation In-Lab PSG Evaluation (ST-1517-ALE-MS)

7/2016: Akili Interactive Labs, Inc. - A study to assess the feasibility of and to characterize Project: EVO Monitor game-play cognitive function measurements when played daily, weekly, or multiple times per day in adults 40-55 years old (Akili-026)

9/2016: Philips Respiroics - In-lab PSG Evaluation of Two Philips ASV Devices (ST-PHASV-16092-JP)

4/2017: Philips Respironics - A Double-Blind Placebo-Controlled Multi-Site Randomized Cross-Over Study of the Effectiveness and Efficacy of the PowerSleep device (AI-16128-PSPIV-LO)

### Training Documentation

May 2020	American Heart Association BLS for Healthcare Providers (CPR & AED) Program
May 2020	IATA Training – Mayo Clinic
April 2020	Janssen – Handling Controlled Substances in Clinical Trials – 2020 Update version 1.0
March 2020	Pro-ficiency – Otsuka’s Good Clinical Practice Training, ICH E6 (R2)
February 2020	Medidata RAVE e-Consent
January 2020	Otsuka Syneos Safety Vigilance Training – Safety Notification Training v1.0
December 2019	iMedidata RAVE RTSM
December 2019	iMedidata RAVE eCOA
November 2019	Trialbee training in online recruitment & the Trialbee Candidate Manager
October 2019	Spaulding ECG training
October 2019	Covance Central Laboratory Service (CCLS) Procedures training
October 2019	Otsuka’s Global Pharmacovigilance Safety Training
September 2019	C-SSRS Refresher training V.1.2 – Blue Cloud
September 2019	Premier DataLabs v5.6 Bridge Site Users
August 2019	Janssen/DrugDev ICH GCP Interventional Version 2.0
August 2019	Janssen/DrugDev Investigator Safety Training Interventional Version 4.0
August 2019	Janssen/DrugDev Handling Controlled Substances in Clinical Trials Version 1.0
April 2019	DataLabs EDC Bridge for Site Users v5.4
March 2019	Medidata Rave EDC
March 2019	rED Cap Training – BioStat International, Inc.
March 2019	CTS Database training
February 2019	DataLabs Premier Study Coordinator v5.6
January 2019	DataLabs EDC: Data Entry v5.6
October 2018	ICON/Firecrest ICH GCP (R2) Investigator Site Training – V2.0
October 2018	Janssen/DrugDev/TransCelerate – ICH GCP Training V2.0

September 2018	SecureConsent Site Staff Training
September 2018	Oracle IRT 5.5 Sites training
September 2018	Oracle InForm 5.5 for Site Users training
September 2018	Oracle InForm 6.1 for Site Users training
June 2018 E6 R2)	Pro-ficiency, LLC (ProCT) – Otsuka Good Clinical Practice Training (ICH Guidelines for GCP
May 2018	American Heart Association BLS for Healthcare Providers (CPR & AED) Program
May 2018	IATA Training – Mayo Clinic
May 2018	Otsuka's Good Clinical Practice Training, ICH E6 (R2)
April 2018	Clinical Ink SureSource, Insight, Capture & Coordinator Module training
April 2018	IATA training / Transporting Dangerous Goods
April 2018	CITI training
April 2018	GCP training
April 2016	IATA Training Transporting Dangerous Goods
July 2016	SOCRA re-certification
April 2015	CITI Program
June 2014	National Institutes of Health Web Base Training: Protecting Human Research Participants
March 2014	IATA training
October 2013	Stericycle Blood Borne Pathogen training
September 2013	SOCRA CCRP re-certification
June 2012	National Institutes of Health Web Base Training: Protecting Human Research Participants
March 2012	IATA training
June 2011	SOCRA CCRP certification
January 2011	IATA training

<b>July 2010</b>	<b>Quintiles ICH/GCP Training for Clinical Sites</b>
<b>June 2010</b>	<b>National Institutes of Health Web Base Training: Protecting Human Research Participants</b>
<b>January 2010</b>	<b>InForm 4.6 Phase Forward training</b>
<b>April 2009</b>	<b>IATA training</b>
<b>December 2008</b>	<b>Pfizer OC-RDC 4.5.3 training</b>
<b>January 2008</b>	<b>Stericycle Blood Borne Pathogen training</b>
<b>December 2007</b>	<b>Pfizer Investigator Site Data Capture course</b>



# The Society of Clinical Research Associates

Certifies by this document that

*Kelly D. Knight, CCRP*

having satisfactorily completed all the stated requirements has been granted the designation

**Certified Clinical Research Professional**

*In testimony whereof are appended the signatures of the  
President and Chairperson of the Certification Committee of this Society*

*Jamie M Harper*  
Jamie M. Harper, MHA, CCRP  
President



*Donna Headlee*

Donna Headlee, RN, BSN, CCRP  
Chairperson, Certification Committee



Completion Date 18-Apr-2021  
Expiration Date 17-Apr-2024  
Record ID 40405444

This is to certify that:

**Kelly Knight**

Has completed the following CITI Program course:

**Group 1: Principal Investigators, Co-Investigators and Research Staff**  
(Curriculum Group)

**Group 1: Principal Investigators, Co-Investigators and Research Staff**  
(Course Learner Group)

**3 - Refresher Course**  
(Stage)

Not valid for renewal of certification through CME.

Under requirements set by:

**Baptist Health Medical Center - Little Rock**



Verify at [www.citiprogram.org/verify/7w6dcf3c20-c867-4a13-bb5e-fe00cbe73f9b-40405444](http://www.citiprogram.org/verify/7w6dcf3c20-c867-4a13-bb5e-fe00cbe73f9b-40405444)

# Certificate of Completion

CERTIFIES THAT

**Kelly Knight**

has participated in the educational activity titled

## **RFMH-A002 - The C-SSRS Training - English V.1.0**

This is the training component containing the video presentation and 8 case studies for you to review. Presented by Kelly Posner, PhD © Research Foundation for Mental Hygiene (RFMH). Completion certificate is valid for a maximum of 2 years.

on

**Tuesday, August 17, 2021 CST**